ANGO Stock Analysis: AngioDynamics | NASDAQ
Medical Instruments & Supplies | NASDAQ, USA | Market Cap: 497m USD | 12M Return: -1.3% | US03475V1017 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 8.74M
Qual. Beats: 1
Rev. Trend: 9.6%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
AngioDynamics, Inc. (NASDAQ: ANGO) is a U.S.-based medical technology company that designs, manufactures, and sells devices used to treat cardiovascular disease and cancer, operating in both domestic and international markets. The company reports through two business segments, Med Tech and Med Device, a structure commonly used by diversified medical device manufacturers to separate higher-growth therapeutic platforms from more established product lines.
Its product portfolio spans several clinical areas, including atherectomy (Auryon), mechanical thrombectomy and thrombolysis (AlphaVac, AngioVac, thrombolytic catheters), irreversible electroporation ablation (NanoKnife), microwave tissue ablation (Solero), endovenous laser therapy (VenaCure EVLT), and a range of peripheral access products such as catheters, guidewires, microintroducer kits, and ports. As a medical device manufacturer, AngioDynamics sells primarily to hospitals and clinicians and is subject to U.S. Food and Drug Administration (FDA) regulatory pathways such as 510(k) clearances and Premarket Approval (PMA) for its therapeutic systems.
Founded in 1988 and headquartered in Latham, New York, AngioDynamics is classified as a small-cap healthcare equipment company within the GICS Health Care sector.
- Auryon Atherectomy system drives Med Tech segment revenue growth
- NanoKnife IRE Ablation System adoption accelerates in oncology procedures
- AlphaVac thrombectomy launch gains traction in emergent care market
| Net Income: -32.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA 5.07 > 1.0 |
| NWC/Revenue: 25.61% < 20% (prev 29.39%; Δ -3.78% < -1%) |
| CFO/TA 0.02 > 3% & CFO 3.67m > Net Income -32.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.40 > 1.5 & < 3 |
| Outstanding Shares: last quarter (42.0m) vs 12m ago 2.06% < -2% |
| Gross Margin: 55.65% > 18% (prev 54.15%; Δ 1.50% > 0.5%) |
| Asset Turnover: 128.2% > 50% (prev 113.2%; Δ 15.00% > 0%) |
| Interest Coverage Ratio: -84.53 > 6 (EBIT TTM -32.4m / Interest Expense TTM 383k) |
| A: 0.34 (Total Current Assets 143.0m - Total Current Liabilities 59.7m) / Total Assets 241.9m |
| B: -1.96 (Retained Earnings -473.0m / Total Assets 241.9m) |
| C: -0.13 (EBIT TTM -32.4m / Avg Total Assets 253.8m) |
| D: 2.10 (Book Value of Equity 164.0m / Total Liabilities 78.0m) |
| Altman-Z'' = -2.76 = D |
| DSRI: 0.97 (Receivables 44.9m/42.6m, Revenue 325.4m/300.7m) |
| GMI: 0.97 (GM 54.15% / 55.65%) |
| AQI: 1.00 (AQ_t 0.29 / AQ_t-1 0.29) |
| SGI: 1.08 (Revenue 325.4m / 300.7m) |
| TATA: -0.15 (NI -32.9m - CFO 3.67m) / TA 241.9m) |
| Beneish M = -3.03 (Cap -4..+1) = AA |
As of November 10, 2026, the stock is trading at USD 12.12 with a total of 609,505 shares traded. Over the past week, the price has changed by +3.06%, over one month by +5.21%, over three months by -23.05% and over the past year by -1.30%.
Current recommended Stop Loss: 10.90 (which is 10.1% or 2 ATR below the current price).
AngioDynamics has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy ANGO.
- StrongBuy: 4
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 19.8 | 63% |
P/E Forward = 208.3333
P/S = 1.5264
P/B = 3.0112
P/EG = 1.4079
Revenue TTM = 325.4m USD
EBIT TTM = -32.4m USD
EBITDA TTM = -9.87m USD
Long Term Debt = 8.94m USD (estimated: total debt 10.7m - short term 1.80m)
Short Term Debt = 1.80m USD (from shortTermDebt, last quarter)
Debt = 10.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -23.2m USD (calculated: Debt 10.7m - CCE 34.0m)
Enterprise Value = 473.4m USD (496.7m + Debt 10.7m - CCE 34.0m)
Interest Coverage Ratio = -84.53 (Ebit TTM -32.4m / Interest Expense TTM 383k)
EV/FCF = 327.9x (Enterprise Value 473.4m / FCF TTM 1.44m)
FCF Yield = 0.31% (FCF TTM 1.44m / Enterprise Value 473.4m)
FCF Margin = 0.44% (FCF TTM 1.44m / Revenue TTM 325.4m)
Net Margin = -10.12% (Net Income TTM -32.9m / Revenue TTM 325.4m)
Gross Margin = 55.65% ((Revenue TTM 325.4m - Cost of Revenue TTM 144.3m) / Revenue TTM)
Gross Margin QoQ = 59.37% (prev 57.06%)
Tobins Q-Ratio = 1.96 (Enterprise Value 473.4m / Total Assets 241.9m)
Interest Expense / Debt = 3.57% (Interest Expense 383k / Debt 10.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -25.6m (EBIT -32.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.40 (Total Current Assets 143.0m / Total Current Liabilities 59.7m)
Debt / Equity = 0.07 (Debt 10.7m / totalStockholderEquity, last quarter 164.0m)
Debt / EBITDA = 2.35 (negative EBITDA) (Net Debt -23.2m / EBITDA -9.87m)
Debt / FCF = -16.09 (Net Debt -23.2m / FCF TTM 1.44m)
Total Stockholder Equity = 171.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -12.98% (Net Income -32.9m / Total Assets 241.9m)
RoE = -19.25% (Net Income TTM -32.9m / Total Stockholder Equity 171.1m)
RoCE = -17.98% (EBIT -32.4m / Capital Employed (Equity 171.1m + L.T.Debt 8.94m))
RoIC = -15.24% (negative operating profit) (NOPAT -25.6m / Invested Capital 167.8m)
WACC = 6.70% (E(496.7m)/V(507.4m) * Re(6.78%) + D(10.7m)/V(507.4m) * Rd(3.57%) * (1-Tc(0.21)))
Discount Rate = 6.78% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 97.48 | Cagr: 1.73%
[DCF] Terminal Value 75.44% ; FCFF base≈1.44m ; Y1≈1.45m ; Y5≈1.54m
[DCF] Fair Price = 1.12 (EV 23.9m - Net Debt -23.2m = Equity 47.1m / Shares 42.1m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.90 | # QB: 1
Revenue Correlation: 9.58 | Revenue CAGR: 0.56% | SUE: 0.19 | # QB: 0
EPS current Quarter (2026-11-30): EPS=-0.07 | Chg30d=+12.00% | Revisions=+0% | Analysts=3
EPS next Quarter (2027-02-28): EPS=-0.09 | Chg30d=-50.00% | Revisions=-40% | Analysts=3
EPS current Year (2027-05-31): EPS=-0.28 | Chg30d=-4.99% | Revisions=-40% | GrowthEPS=-86.7% | GrowthRev=+5.5%
EPS next Year (2028-05-31): EPS=-0.11 | Chg30d=-151.78% | Revisions=+25% | GrowthEPS=+59.5% | GrowthRev=+5.1%
[Analyst] Revisions Ratio: -30% (up=2, down=5)